Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | BCR | P11274 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29575640 | 0.79 | MKNK1 (0.58) | ROCK1MAP3K5MAP4K1 | |
| SCHEMBL27770482 | 0.76 | MAP3K5 (0.60) | NPC1RAB9ACYP3A4MEN1ALOX15 | |
| Benzene SCHEMBL28188863 | 0.76 | MAP3K5 (0.60) | NPC1RAB9ACYP3A4MEN1ALOX15 | |
| SCHEMBL167891 | 0.76 | MAP3K5 (0.60) | NPC1RAB9ACYP3A4MEN1ALOX15 | |
| SCHEMBL31381352 | 0.76 | MAP3K5 (0.60) | NPC1RAB9ACYP3A4MEN1ALOX15 | |
| SCHEMBL4573935 | 0.75 | MAP3K5 (0.58) | NPC1RAB9ACYP3A4MEN1ALOX15 | |
| Hydrochloric Acid SCHEMBL8807679 | 0.75 | MAP3K5 (0.58) | NPC1RAB9ACYP3A4MEN1ALOX15 | |
| SCHEMBL28484940 | 0.75 | CYP3A4 (0.71) | CYP11B1CYP11B2NPC1CASP3RAB9A | |
| SCHEMBL7535971 | 0.74 | ABL1 (0.55) | CYP3A4ABL1PDGFRBBCRSRC | |
| SCHEMBL6033965 | 0.74 | KDR (0.68) | RAB9AMEN1ALOX15TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC (US) | 2025-09-02 | — | — | US | disclosed |
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC | 2024-06-20 | — | — | US | disclosed |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2022-11-10 | — | — | US | disclosed |
| US-11304957-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2022-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | CYP11B1 3734/4885CYP11B2 3639/4885NPC1 3185/4885 |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | CYP11B1 3734/4885CYP11B2 3639/4885NPC1 3185/4885 |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | CYP11B1 3734/4885CYP11B2 3639/4885NPC1 3185/4885 |
| US-11304957-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | CYP11B1 3734/4885CYP11B2 3639/4885NPC1 3185/4885 |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | CYP11B1 3734/4885CYP11B2 3639/4885NPC1 3185/4885 |
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | BRAF, TTK, MAP4K2 | CYP11B1 3112/4885CYP11B2 2899/4885NPC1 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.